Viewpoint | Published:

Immunological memory: lessons from the past and a look to the future

Nature Reviews Immunology volume 16, pages 124128 (2016) | Download Citation

Abstract

Immunological memory is considered to be one of the cardinal features of the adaptive immune system. Despite being a recognized phenomenon since the time of the ancient Greeks, immunologists are yet to fully appreciate the mechanisms that control memory responses in the immune system. Furthermore, our definition of immunological memory itself continues to evolve, with recent suggestions that innate immune cells also show memory-like behaviour. In this Viewpoint article, Nature Reviews Immunology invites five leading immunologists to share their thoughts on our current understanding of the nature of immunological memory. Our experts highlight some of the seminal studies that have shaped the immune memory field and offer contrasting views on the key questions that remain to be addressed.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    On differences between immunity and immunological memory. Curr. Opin. Immunol. 14, 523–536 (2002).

  2. 2.

    & Immunological memory and protective immunity: understanding their relation. Science 272, 54–60 (1996).

  3. 3.

    Clonal selection and learning in the antibody system. Nature 381, 751–758 (1996).

  4. 4.

    et al. Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proc. Natl Acad. Sci. USA 92, 1257–1261 (1995).

  5. 5.

    , & Primary antibody responses to a well-defined and unique hapten are not enhanced by preimmunization with carrier: analysis in a viral model. Proc. Natl Acad. Sci. USA 83, 2604–2608 (1986).

  6. 6.

    et al. Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs. Proc. Natl Acad. Sci. USA 97, 13263–13268 (2000).

  7. 7.

    Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17, 1055–1065 (2010).

  8. 8.

    et al. The role of antibody concentration and avidity in antiviral protection. Science 276, 2024–2027 (1997).

  9. 9.

    et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 286, 2156–2159 (1999).

  10. 10.

    On natural and artificial vaccinations. Ann. Rev. Immunol. 21, 515–546 (2003).

  11. 11.

    et al. On the role of antigen in maintaining cytotoxic T-cell memory. Proc. Natl Acad. Sci. USA 93, 9716–9723 (1996).

  12. 12.

    et al. Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without “memory T cells”? Proc. Natl Acad. Sci. USA 94, 640–645 (1997).

  13. 13.

    et al. Induction of long-lived germinal centers associated with persisting antigen after viral infection. J. Exp. Med. 183, 2259–2269 (1996).

  14. 14.

    et al. Long-lasting immunity by early infection of maternal-antibody-protected infants. Eur. J. Immunol. 40, 113–116 (2010).

  15. 15.

    et al. Somatic mutation and the maturation of immune response to 2-phenyl oxazolone. Nature 312, 271–275 (1984).

  16. 16.

    Epidemic pertussis in 2012—the resurgence of a vaccine-preventable disease. N. Engl. J. Med. 367, 785–787 (2012).

  17. 17.

    & Innate lymphoid cells in the initiation, regulation and resolution of inflammation. Nat. Med. 21, 698–708 (2015).

  18. 18.

    , & Natural killer cell memory. Immunity 43, 634–645 (2015).

  19. 19.

    , , & Priming for enhanced defense. Annu. Rev. Phytopathol. 53, 97–119 (2015).

  20. 20.

    Specific memory within innate immune systems. Trends Immunol. 26, 186–192 (2005).

  21. 21.

    et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 16, 223–232 (2012).

  22. 22.

    et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 345, 1251086 (2014).

  23. 23.

    et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 42, 443–456 (2015).

  24. 24.

    et al. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity 42, 431–442 (2015).

  25. 25.

    Resistance to intracellular infection. J. Infect. Dis. 123, 439–445 (1971).

  26. 26.

    & Macrophage activation in mice lacking thymus-derived (T) cells. Experientia 31, 591–593 (1975).

  27. 27.

    et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708–712 (1999).

  28. 28.

    et al. Functionally heterogeneous CD8+ T-cell memory is induced by Sendai virus infection of mice. J. Virol. 73, 7278–7286 (1999).

  29. 29.

    , & Heterogeneity of the memory CD4 T cell response: persisting effectors and resting memory T cells. J. Immunol. 166, 926–935 (2001).

  30. 30.

    et al. Preferential localization of effector memory cells in nonlymphoid tissue. Science 291, 2413–2417 (2001).

  31. 31.

    & Hidden memories: frontline memory T cells and early pathogen interception. J. Immunol. 188, 5811–5817 (2012).

  32. 32.

    et al. Cutting edge: tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J. Immunol. 187, 5510–5514 (2011).

  33. 33.

    et al. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat. Immunol. 10, 524–530 (2009).

  34. 34.

    & A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 491, 463–467 (2012).

  35. 35.

    et al. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science 348, aaa8205 (2015).

  36. 36.

    , & Effector T cell differentiation: are master regulators of effector T cells still the masters? Curr. Opin. Immunol. 37, 6–10 (2015).

  37. 37.

    M1 and M2 macrophages: oracles of health and disease. Crit. Rev. Immunol. 32, 463–488 (2012).

  38. 38.

    et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8, 177–187 (1998).

  39. 39.

    et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4, 225–234 (2003).

  40. 40.

    et al. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4, 1191–1198 (2003).

  41. 41.

    et al. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J. Exp. Med. 195, 1523–1532 (2002).

  42. 42.

    , , & Humoral immunity due to long-lived plasma cells. Immunity 8, 363–372 (1998).

  43. 43.

    et al. Long-lived plasma cells are contained within the CD19CD38hiCD138+ subset in human bone marrow. Immunity 43, 132–145 (2015).

  44. 44.

    et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058–1064 (2001).

  45. 45.

    et al. Antigen kinetics determines immune reactivity. Proc. Natl Acad. Sci. USA 105, 5189–5194 (2008).

  46. 46.

    & The antibody response of rats depleted of lymphocytes by chronic drainage from the thoracic duct. J. Exp. Med. 117, 303–320 (1963).

  47. 47.

    et al. Memory CD8+ T cells colocalize with IL-7+ stromal cells in bone marrow and rest in terms of proliferation and transcription. Eur. J. Immunol. 45, 975–987 (2015).

  48. 48.

    et al. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. 191, 795–804 (2000).

Download references

Author information

Affiliations

  1. Donna L. Farber is at the Columbia Center for Translational Immunology, Department of Surgery, Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York 10032, USA.

    • Donna L. Farber
  2. Mihai G. Netea is at the Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, 6525 GA Nijmegen, Netherlands.

    • Mihai G. Netea
  3. Andreas Radbruch is at the Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), a Leibniz Institute, Charitéplatz 1, 10117 Berlin, Germany.

    • Andreas Radbruch
  4. Klaus Rajewsky is at the Immune Regulation and Cancer, Max Delbrück Center for Molecular Medicine in the Helmholtz Alliance, Berlin-Buch 13125, Germany.

    • Klaus Rajewsky
  5. Rolf M. Zinkernagel is at the Institute for Experimental Immunology, University Hospital Zürich, CH-8091 Zürich, Switzerland.

    • Rolf M. Zinkernagel

Authors

  1. Search for Donna L. Farber in:

  2. Search for Mihai G. Netea in:

  3. Search for Andreas Radbruch in:

  4. Search for Klaus Rajewsky in:

  5. Search for Rolf M. Zinkernagel in:

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Donna L. Farber or Mihai G. Netea or Andreas Radbruch or Klaus Rajewsky or Rolf M. Zinkernagel.

Glossary

Germinal centre

A transient, highly organized multicellular structure present within B cell follicles that is a site for the generation of memory B cells and long-lived plasma cells, as well as for affinity maturation of antibodies.

Hapten

A molecule that can be bound by an antibody but cannot elicit an immune response by itself. Antibodies that are specific for a hapten can be generated when the hapten is chemically linked to a protein carrier that can elicit a T cell response. Haptens have no biological significance, as all relevant determinants of immunity (antigens) involve complex tertiary structures with antibody contact areas of approximately 8–15 amino acids or T cell peptide epitopes of 9–11 amino acids presented by MHC molecules.

Heterologous immunity

Also known as 'infection immunity'. Immunity that develops against a pathogen after the host has been exposed to a non-identical pathogen.

Somatic hypermutation

A programmed process of mutation targeting the variable regions of immunoglobulin genes that allows the selection of B cells that express immunoglobulin receptors with the highest affinity for antigens.

Systemic acquired resistance

(SAR). A state of enhanced immunity to infection in plants that occurs throughout the whole plant after it has been subjected to an initial, localized injury.

Trained immunity

Also referred to as 'innate memory'. The long-term improvement of the function of innate immune cells after infection or vaccination, owing to epigenetic rewiring of cellular functional programmes.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nri.2016.13

Further reading